beta-glucan elicits APOE-dependent peripheral trained immunity to suppress hepatocellular carcinoma.
A immune-boosting sugar particle combined with checkpoint immunotherapy shrank liver tumors more effectively than either treatment alone in preclinical models.
Whole beta-glucan particle preconditioning induces a trained immunity phenotype in APOE-positive hepatic macrophages, reducing lipid accumulation and endoplasmic reticulum stress to enhance antitumor function in orthotopic HCC models. Combination with anti-PD-L1 achieves superior tumor control vs either monotherapy, with the mechanism validated in human monocytes supporting translational applicability.
What the study was
- Study design
- original_research
- Population
- Orthotopic HCC mouse models; human monocyte training assays
- Category
- Immunotherapy / HCC
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
Novel APOE-dependent trained immunity mechanism for HCC immunotherapy; beta-glucan WGP is clinically safe and widely available; superior combo with anti-PD-L1; scRNA-seq + adoptive transfer mechanistic rigor; human monocyte validation; J Immunother Cancer.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.